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LETTERS
Crohn’s associated NOD2 gene
variants are not involved in
determining susceptibility to
multiple sclerosis
Autoimmune diseases, such as multiple scle-
rosis and Crohn’s disease, are believed to
result from the effects of environmental
agents acting on genetically susceptible indi-
viduals. Evidence from segregation analysis
and systematic whole genome linkage studies
indicates that the nature of this susceptibility
is complex, involving several genes which
each individually confer only modest excess
risk. Recurrence risk analysis in the relatives
of affected individuals1 together with the
comparison of whole genome linkage studies
across these diseases2 shows that there are
likely to be both genes conferring an auto-
immune diathesis in general and others
determining precisely which autoimmune
phenotype may result. On this basis it is
reasonable to hypothesise that genes shown
to be relevant in one autoimmune disease
may be of importance in another and there-
fore offer themselves as potential candidates.
During the last few years striking progress
has been made in unravelling the genetic basis
of susceptibility to Crohn’s disease. Significant
evidence for linkage in the pericentromeric
region of chromosome 16 has been found,3 fol-
lowing on from which two independent
groups, one using association mapping4 and
the other following a candidate gene
approach,5 identified the relevant gene as
NOD2. Three variants of this gene (IBD8,
IBD12, and IBD13) were shown to influence
susceptibility to Crohn’s disease. IBD8 is a mis-
sense mutation in exon 3 (2023C>T, R675W);
IBD12 is a missense mutation in exon 7
(2641G>C, G1881R); and IBD13 is a
frameshift variant in exon 10 (2936insC,
980fs981X). Although precise functions of the
NOD2 gene are not fully known it is believed to
have important immunological activity, par-
ticularly in maintaining symbiosis between the
gut lining and its commensal bacteria.
Given the established importance of these
variants in determining susceptibility to one
autoimmune disease (Crohn’s disease), we
examined their role in a second by genotyping
all three variants in a large number of patients
with multiple sclerosis (n = 631) and a cohort
of controls (n = 343).
All individuals taking part in this study
gave informed written consent for genetic
analysis. Each individual gave a venous blood
sample from which DNA was extracted using
standard methods. Genotyping was under-
taken using Applied Biosystems multiplex
primer extension assay system (Multiplex
SNaPshot). Primers for primary PCR amplifi-
cation and extension reactions are shown in
table 1. Electrophoresis was done on a 3700
DNA analyser with genotyping completed
using the GENSCAN/GENOTYPER software
systems. Statistical analysis was by χ2 testing.
The observed allele frequencies are shown
in table 1. No statistically significant differ-
ence in allele frequency was seen for IBD8
(χ2 = 1.57, p = 0.21), IBD12 (χ2 = 0.002,
p = 0.96), or IBD13 (χ2 = 2.78, p = 0.10). In
each case, the observed allele frequency was
commensurate with that previously observed
in the Crohn’s disease studies (table 1).
Our results indicate that the NOD2 gene is
probably not influencing susceptibility to
autoimmune disease in general but is specific
for Crohn’s disease.
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Favourable outcome of a brain
trauma patient despite bilateral
loss of cortical somatosensory
evoked potential during
thiopental sedation
We would like to present an observation that
somewhat questions the predictive value of
somatosensory evoked potentials on the out-
come of brain trauma patients treated with
thiopental coma.1 2
A 30 year old woman suffered a high veloc-
ity car accident resulting in a diffuse brain
injury. Her Glasgow coma scale score on
admission was E2V2M5 (9/15), with preserved
pupillary reflexes and gross motor function.
Computed tomography of the head showed a
traumatic disjunction of the lambdoid suture
and multiple left frontobasal and temporal
cerebral contusions. The patient was sedated
with propofol, intubated, and monitored for
intracerebral pressure (ICP) through an exter-
nal ventricular drain. Her clinical condition
rapidly worsened because of brain swelling
around the contusions, and cerebrospinal
fluid drainage, manitol boluses, and mild
hyperventilation were started. Three days
after admission, a further ICP increase was
treated with thiopental coma (10 mg/kg/h ×
24 h loading dose followed by 3 mg/kg/h
maintenance dose to obtain a burst suppres-
sion EEG pattern). On day 7, the patient
developed a left sided mydriasis and a left
temporal partial lobectomy was performed to
remove contused brain. The ICP returned to
normal and thiopental administration was
stopped on day 8. On day 10, the EEG was iso-
electrical and on day 11, somatosensory
evoked potentials (SSEP) of the median nerve
showed no cortical response (N20) despite
normal brachial plexus (Erb) and lemniscal
(P14) potentials. Levels of thiopental and
phenobarbital, its main metabolite, were then
respectively 65 ng/l and 56 ng/l. The patient
remained areactive (GCS 3/15T) and without
brain stem reflexes, including the ocular-
cardiac response, until day 20. The transcra-
nial Doppler however showed normal flow
patterns and the brain CT scan did not reveal
any post-herniation ischaemic lesion. On day
21, the patient opened her eyes. The serum
concentration of thiopental was then 12 ng/l
whereas that of phenobarbital remained
around 40 ng/l until day 23. A 1–2 Hz low
amplitude EEG activity with right sided
predominance was observed, and the SSEP
cortical peak N20 recovered on day 22 when
the thiopental concentration was 5.9 ng/l. A
steady improvement followed. On discharge
to a rehabilitation facility (day 57), the patient
could follow simple commands but suffered
mixed dysphasia and generalised weakness.
At four months, she presented no residual
motor deficit, an improved verbal expression
and comprehension, and a moderate frontal
behaviour. At two years, the patient only still
suffered some episodes of labile mood, and
although she had not resumed her previous
job, she was active as a farm worker, read and
wrote, drove her car, and could live an
independent and social life, with a Glasgow
outcome score (GOS) of 5/5.
SSEP are commonly used to monitor coma-
tose patients even under barbiturate
sedation.2 3 Indeed, although their morphol-
ogy can become changed, short latency SSEPs
Table 1 Observed frequency of Crohn’s disease associated alleles in
multiple sclerosis
Variant Multiple sclerosis (%) Controls (%)
Published control frequency
(%)
IBD8* 54 (4.8) 34 (6.2) 4
IBD12 11 (0.9) 6 (0.9) 1
IBD13 28 (2.3) 8 (1.2) 2
*The primary PCR for this assay was relatively unreliable such that typing success rate was 90%
for cases and 80% for controls. Both of the other assays had typing success rates of greater than
95%. The manufacturer’s standard reaction conditions were used for all reactions except the
primary amplification of IBD8 where a lower annealing temperature of 50°C was used along with
four additional PCR cycles.
Primary PCR primers
IBD8: ACCTTCAGATCACAGCAGCC and GCTCCCCCATACCTGAAC
IBD12: AAGTCTGTAATGTAAAGCCA and CCCAGCTCCTCCCTCTTC
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in humans supposedly do not disappear in
response to barbiturate doses sufficient to
render the EEG isoelectrical and the neuro-
logical examination similar to brain stem
death.3 4 The bilateral loss of SSEP N20
responses is regarded as a predictor of
ominous outcome after a trauma. There are
only a few reports on the recovery of initially
absent or lost N20 potentials after severe brain
injury with increased ICP, some of them with
a good outcome as was the case in our
patient.5 6 In our case, the disappearance of
the cortical evoked responses correlated with
both the ICP increase and the induction of
thiopental coma. As their reappearance
closely matched the elimination of thiopental
from the bloodstream and was quite delayed
relative to the normalisation of the ICP, our
observation suggests that barbiturates may
contribute to the suppression of N20 evoked
potentials in brain trauma patients. Awaiting
further observations, caution is thus war-
ranted on the use of SSEP to monitor the
clinical evolution and predict the outcome of
such patients under barbiturate coma.
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mutation for the myoclonus
epilepsy and ragged red fibres
(MERRF) syndrome
The myoclonus epilepsy and ragged red fibres
(MERRF) syndrome is a maternally inherited
progressive mitochondrial encephalomyopa-
thy caused by a 8344A>G mutation in the
MTTK gene that encodes mitochondrial tRNA
for lysine. Its common clinical features in-
clude myoclonic and tonic-clonic seizures,
ataxia, and myopathy, but other features have
also been reported, including lipoma, diabetes
mellitus, optic atrophy, peripheral neuropathy,
hearing loss, and dementia.1
The population frequencies of pathogenic
mutations in mitochondrial DNA (mtDNA)
are not well known, but the Finnish health-
care organisation provides good opportunities
to carry out studies on molecular epidemiol-
ogy. We have previously determined the
frequency of 3243A>G, the most common
cause of the MELAS syndrome (mito-
chondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes), to be 16/100 000 in
the adult population of Northern
Ostrobothnia.2 We report here on the identifi-
cation of patient groups with common clinical
features of the MERRF syndrome, in a
comparable population and the resulting
determination of the prevalence of the
8433A>G mtDNA mutation.
Patients and methods
The prevalence area considered here is the
province of Northern Ostrobothnia in north-
ern Finland, with a total population of
353 895 on 31 December 1994 (prevalence
date), including 245 201 persons>20 years of
age. Adult patients with diagnoses that are
commonly associated with the 8344A>G
mutation1 were identified as being at risk with
respect to mitochondrial disorders, and we
therefore screened the population for patients
>20 years of age who had disorders such as
ataxia, diabetes mellitus, epilepsy, lipoma,
myopathy, ophthalmoplegia, optic atrophy,
peripheral neuropathy, and sensorineural
hearing impairment (table 1). These were
Table 1 Criteria used in the screening of the patient groups













Ataxia Any ataxia, unknown aetiology 79 Idiopathic cerebellar ataxia, age >20 years at visit 39 26 (67)
Diabetes* Insulin treatment started at age 20–45
years
479 Family history of mitochondrial phenotype† 169 143 (85)
Epilepsy‡ Age >20 years at visit, response to
family history questionnaire
945 Family history of mitochondrial phenotype† 223 165 (74)
Hearing loss§ Sensorineural hearing impairment,
hearing aid obtained at age <45
years, current age >20 years
242 Family history of mitochondrial phenotype† 108 82 (76)
Lipoma Any lipoma 621 Axial or multiple lipomas, age >20 years at visit 150 107 (71)
Myopathy Any myopathy with clinical and EMG
verification, age >20 years at visit
146 Myopathy of unknown aetiology or any muscle
dystrophy¶
41 32 (78)
Neuropathy Any electrophysiologically defined
idiopathic neuropathy, age >20 years
at visit
138 Familial neuropathy or family history of mitochondrial
phenotype†
31 21 (68)
Ophthalmoplegia Double vision or ptosis, any age 799 Definite ophthalmoplegia or symmetric ptosis,
age >20 years at examination
15 15 (100)
Optic atrophy Decrease in visual acuity or optic disc
abnormality, any cause, any age
1542 Optic atrophy of unknown aetiology**, current
age >20 years
42 30 (71)
Total 4991 Total 818 621 (76)
OUH; Oulu University Hospital. Computer search at OUH was first performed to identify patients with specific discharge diagnoses that had been filed
according to Finnish version of the International Statistical Classification of Diseases and Related Health Problems. Specific selection criteria were then
applied to select patients with definite diagnoses. *Patients with insulin dependent diabetes mellitus obtain needles, syringes, insulin pens, and glucose
sticks free of charge from the public health care units, and the supplies used are recorded. These patients were identified from the records of 40 of the 42
local authority health care units. Discharge diagnoses at one of the two regional hospitals in the area and the diabetes register of the other also were
reviewed. †Patients with any combination of diabetes mellitus, sensorineural hearing impairment or epilepsy in first or second degree maternal relatives
were included. ‡Most adult patients with epilepsy make regular follow up visits to the outpatient clinic of the department of neurology at OUH at least once
a year. During a one year period, a physician involved in the study checked the charts of the patients visiting the clinic every day. The diagnosis of
epilepsy was confirmed on this occasion, and patients receiving regular antiepileptic medication were included. No distinction was made between the
types or aetiologies of epilepsy. §The cost of hearing aids is refunded in full by the public health service, and aids are supplied in the region only by the
department of otorhinolaryngology at OUH. The register of hearing aids supplied was reviewed and patients were ascertained on the basis of the
following clinical criteria: symmetric sensorineural hearing impairment with undefined aetiology; hearing impairment >30 dB (pure tone average of
frequencies 0.5, 1, 2, and 4 kHz); a difference between the ears <10 dB; and use of a hearing aid at age <45 years. ¶Duchenne muscular dystrophy
and other myopathies with definite molecular genetic diagnosis were excluded. **Demyelinating diseases and ischaemic diseases were excluded.
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